These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 11028832)

  • 41. Possible involvement of 5-HT4 receptors, in addition to 5-HT3 receptors, in the emesis induced by high-dose cisplatin in Suncus murinus.
    Horikoshi K; Yokoyama T; Kishibayashi N; Ohmori K; Ishii A; Karasawa A
    Jpn J Pharmacol; 2001 Jan; 85(1):70-4. PubMed ID: 11243577
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tropisetron for postoperative nausea and vomiting in patients after gynaecological surgery.
    Zomers PJ; Langenberg CJ; de Bruijn KM
    Br J Anaesth; 1993 Nov; 71(5):677-80. PubMed ID: 8251279
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
    Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
    Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Distler O; Eich W; Dokoupilova E; Dvorak Z; Fleck M; Gaubitz M; Hechler M; Jansen JP; Krause A; Bendszus M; Pache L; Reiter R; Müller-Ladner U
    Arthritis Rheum; 2010 Jan; 62(1):291-300. PubMed ID: 20039417
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tropisetron, a new 5-HT3 receptor antagonist, in the prevention of irradiation-induced nausea, vomiting and diarrhoea.
    Sorbe B; Berglind AM; De Bruijn K
    Eur J Gynaecol Oncol; 1992; 13(5):382-9. PubMed ID: 1486916
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunomodulatory function of the 5-HT3 receptor antagonist tropisetron.
    Schneider EM; Ma X; Stratz T; Müller W; Lorenz I; Seeling WD
    Scand J Rheumatol Suppl; 2004; 119():34-40. PubMed ID: 15515411
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Local treatment of periarthropathies with the 5-HT3-receptor-antagonist tropisetron].
    Stratz T; Stauber A; Müller W
    Z Orthop Ihre Grenzgeb; 2002; 140(4):394-8. PubMed ID: 12183788
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tropisetron for the prevention of postoperative nausea and vomiting in women undergoing gynecologic surgery.
    Alon E; Kocian R; Nett PC; Koechli OR; Baettig U; Grimaudo V
    Anesth Analg; 1996 Feb; 82(2):338-41. PubMed ID: 8561338
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An open, randomized study to compare the efficacy and tolerability of tropisetron with that of a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.
    Sorbe B; Hallén C; Frankendal B
    Cancer Chemother Pharmacol; 1994; 33(4):298-302. PubMed ID: 8281622
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Once daily controlled-release pregabalin in the treatment of patients with fibromyalgia: a phase III, double-blind, randomized withdrawal, placebo-controlled study.
    Arnold LM; Arsenault P; Huffman C; Patrick JL; Messig M; Chew ML; Sanin L; Scavone JM; Pauer L; Clair AG
    Curr Med Res Opin; 2014 Oct; 30(10):2069-83. PubMed ID: 24867298
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications.
    Holman AJ; Myers RR
    Arthritis Rheum; 2005 Aug; 52(8):2495-505. PubMed ID: 16052595
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The anti-emetic efficacy of tropisetron plus dexamethasone in patients treated with high-dose chemotherapy and stem cell transplantation.
    Barbounis V; Koumakis G; Hatzichristou H; Vassilomanolakis M; Tsoussis S; Efremidis A
    Support Care Cancer; 1999 Mar; 7(2):79-83. PubMed ID: 10089087
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of tropisetron, a 5-HT3 receptor antagonist, on analgesia and nausea after intrathecal morphine.
    Pitkänen MT; Niemi L; Tuominen MK; Rosenberg PH
    Br J Anaesth; 1993 Nov; 71(5):681-4. PubMed ID: 8251280
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of tendopathies with tropisetron.
    Stratz T; Varga B; Müller W
    Rheumatol Int; 2002 Nov; 22(6):219-21. PubMed ID: 12426658
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of intravenous tropisetron on modulation of pain and central hypersensitivity in chronic low back pain patients.
    Neziri AY; Dickenmann M; Scaramozzino P; Andersen OK; Arendt-Nielsen L; Dickenson AH; Curatolo M
    Pain; 2012 Feb; 153(2):311-318. PubMed ID: 22100357
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.
    Wilkinson D; Windfeld K; Colding-Jørgensen E
    Lancet Neurol; 2014 Nov; 13(11):1092-1099. PubMed ID: 25297016
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A report comparing the use of tropisetron (Navoban), a 5-HT3 antagonist, with a standard antiemetic regimen of dexamethasone and metoclopramide in cisplatin-treated patients under conditions of severe emesis.
    Madej G; Krzakowski M; Pawinski A; Lasota W; Rogowski W; Skoneczna I
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):3-6. PubMed ID: 9113119
    [TBL] [Abstract][Full Text] [Related]  

  • 59. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy--a randomised study.
    Jantunen IT; Muhonen TT; Kataja VV; Flander MK; Teerenhovi L
    Eur J Cancer; 1993; 29A(12):1669-72. PubMed ID: 8398291
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome.
    Bardhan KD; Bodemar G; Geldof H; Schütz E; Heath A; Mills JG; Jacques LA
    Aliment Pharmacol Ther; 2000 Jan; 14(1):23-34. PubMed ID: 10632642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.